Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
TNFRSF10A 8797 HYDROGEN PEROXIDE CHEMBL71595 NCI 18299966
TNFRSF10A 8797 DULANERMIN CHEMBL2107846 agonist, antibody MyCancerGenome, ChemblInteractions, TTD
TNFRSF10A 8797 SULINDAC CHEMBL15770 NCI 16030090
TNFRSF10A 8797 CHEMBL1790415 CHEMBL1790415 agonist GuideToPharmacologyInteractions
TNFRSF10A 8797 MAPATUMUMAB CHEMBL2108621 agonist, antibody TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
TNFRSF10A rs20576 TT rituximab efficacy no Genotype TT is not associated with response to rituximab in people with Lymphoma, Follicular as compared to genotypes GG + GT. 27977511 1448567593
TNFRSF10A rs20575 CC infliximab efficacy yes The CC genotype was associated with a better response after 6 months of treatment with infliximab. Response to therapy was assessed according to EULAR response criteria. Genotype CC is associated with increased response to infliximab in people with Arthritis, Psoriatic as compared to genotypes CG + GG. 22480748 982046888
TNFRSF10A rs20575 CC infliximab efficacy yes The CC genotype was associated with a better response after 3 and 6 months of treatment with infliximab. Response to therapy was assessed according to EULAR response criteria. Genotype CC is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes CG + GG. 22480748 982046966
TNFRSF10A rs20575 CC adalimumab efficacy yes The CC genotype was associated with a better response after 3 and 6 months of treatment with anti-TNFalpha drugs. Response to therapy was assessed according to EULAR response criteria. Genotype CC is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CG + GG. 22480748 982046870
TNFRSF10A rs20575 CC adalimumab efficacy no No significance association between genotype and response to the anti-TNFalpha drugs after 3 and 6 months of treatment were seen. Response to therapy was assessed according to EULAR response criteria. Genotype CC is not associated with response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CG + GG. 22480748 982046944
TNFRSF10A rs2230229 TT rituximab efficacy no Genotype TT is not associated with response to rituximab in people with Lymphoma, Follicular as compared to genotypes CC + CT. 27977511 1448567608
TNFRSF10A rs20575 GG rituximab efficacy no rs20575 GC/GG carriers (as reported in the article; gene on the negative strand) were more partial/nonresponders (88.2%) than complete responders (72.5%), showing a trend toward statistical significance (P=0.064). Genotype GG is not associated with response to rituximab in people with Lymphoma, Follicular as compared to genotypes CC + CG. 27977511 1448567570